Respra is designed for real-world health systems. From tertiary hospitals to rural clinics to home monitoring, Respra works in every context.
Respra integrates with existing clinical workflows to add fast, non-invasive multi-disease screening at triage, pre-admission, and follow-up stages.
Results export directly to major EHR platforms via HL7 FHIR, embedding into existing patient records without extra workflow steps.
Sub-90-second total cycle time per patient — cartridge swap to result — enabling rapid sequential testing in busy emergency or outpatient departments.
Full HIPAA/GDPR-compliant audit logging. Every test is timestamped, operator-identified, and secured with end-to-end encryption.
Respra gives GPs an affordable, rapid screening tool that flags patients who need specialist referral — reducing missed diagnoses and unnecessary imaging.
The device requires no specialist training. Any clinical staff member can administer a test within a 5-minute onboarding walkthrough.
Risk stratification output is designed to support — not replace — GP clinical judgment, with clear confidence bands and recommended next steps.
Single-use cartridge model keeps per-test cost competitive with standard blood panels, enabling routine use rather than specialist referral only.
For chronic disease monitoring and longitudinal health tracking, Respra's consumer-grade variant enables patients to test from home and share results with their care team.
Mobile app for iOS and Android guides the patient through testing, stores historical results, and pushes trend alerts to connected clinicians.
Longitudinal VOC tracking reveals disease progression or treatment response over time — far richer than one-time snapshots.
On-device computation for primary analysis. Cloud sync optional and fully consent-gated, with granular data sharing controls.
Respra's throughput, low cost, and zero-specialist-required design make it uniquely suited to large-scale national screening programs and workplace health initiatives.
Compact form factor enables deployment in community centres, schools, workplaces, and mobile health vans without infrastructure requirements.
Aggregated, anonymized data across screening cohorts generates population-level disease prevalence insights for public health authorities.
Self-contained screening station — device, cartridges, display, and connectivity — ships as a single deployable unit, operational in under 20 minutes.
Build Gen-1 device prototype, establish biomarker library, and run initial clinical validation studies with academic hospital partners.
2026 — CurrentSubmit for FDA Breakthrough Device designation and CE Mark. Run 500-patient clinical pilot across 3 hospital sites.
2027Launch Respra device and clinical platform to early hospital and GP clinic partners. Begin home monitoring beta program.
2028Respra is built on tiered pricing, recurring per-test fees, and a long-term commitment to at-cost deployment where disease burden is highest.